|
1) Adcock IM, Chung KF, Caramori G, et al. Kinase inhibitors and airway inflammation. Euro J Pharmacol. 2006; 533: 118
|
|
|
|
|
2) Di Stefano A, Caramori G, Oates T, et al. Increased expression of nuclear factor-kappa B in bronchial biopsies from smokers and patients with COPD. Eur Respir J. 2002; 20: 556-63
|
|
|
|
|
3) Saklatvala J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol. 2004; 4: 372
|
|
|
|
|
|
4) Smith SJ, Fenwick PS, Nicholson AG, et al. Inhibitory effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages. Br J Pharmacol. 2006; 149: 393- 404
|
|
|
|
|
|
5) Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev. 2001; 81: 807-69
|
|
|
|
|
|
6) Craxton A, Shu G, Graves JD, et al. p38 MAPK is required for CD40-induced gene expression and proliferation in B lymphocytes. J Immunol. 1998; 161: 3225-36
|
|
|
|
|
|
7) Lee JC, Kumar S, Griswold DE, et al. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology. 2000; 47: 185
|
|
|
|
|
|
8) Renda T, Baraldo S, Pelaia G, et al. Increased activation of p38 MAPK in COPD. Eur Respir J. 2008; 31: 62-9
|
|
|
|
|
|
9) Cohen P. Protein kinases-the major drug targets of the twenty-first century？ Nat Rev Drug Discov. 2002; 1: 309-15
|
|
|
|
|
|
10) Kankaanranta H, De Souza PM, Barnes PJ, et al. SB 203580, an inhibitor of p38 mitogen-activated protein kinase, enhances constitutive apoptosis of cytokine-deprived human eosinophils. J Pharmacol Exp Ther. 1999; 290: 621-8
|
|
|
|
|
|
11) Escott KJ, Belvisi MG, Birrell MA, et al. Effect of the p38 kinase inhibitor, SB 203580, on allergic airway inflammation in the rat. Br J Pharmacol. 2000; 131: 173-6
|
|
|
|
|
|
12) Underwood DC, Osborn RR, Bochnowicz S, et al. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol. 2000; 279: L895-902
|
|
|
|
|
|
13) Kuma Y, Sabio G, Bain J, et al. BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. J Biol Chem. 2005; 280: 19472-9
|
|
|
|
|
|
14) Branger J, van den Blink B, Weijer S, et al. Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endo-toxemia. J Immunol. 2002; 168: 4070-7
|
|
|
|
|
|
15) Schreiber S, Feagan B, D'Haens G, et al. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: A Randomized, Double-Blind, Placebo-Controlled Trial. Clin Gastroenterol Hepatol. 2006; 4: 325
|
|
|
|
|
|
16) Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009; 60: 1232-41
|
|
|
|
|
|
17) Trifilieff A, Keller TH, Press NJ, et al. CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phospho-diesterase type 4 inhibitor with potent in vitro and in vivo anti-inflammatory activities. Br J Pharmacol. 2005; 144: 1002-10
|
|
|
|
|
|
18) Mark CG. Inhibition of p38: Has the fat lady sung？ Arthritis & Rheumatism. 2009; 60: 317-20
|
|
|
|
|
|
19) Kotlyarov A, Neininger A, Schubert C, et al. MAPKAP kinase 2 is essential for LPS-induced TNF-[alpha] biosynthesis. Nat Cell Biol. 1999; 1: 94
|
|
|
|
|
|
20) Duan W, Chan JHP, McKay K, et al. Inhaled p38{alpha} mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am J Respir Crit Care Med. 2005; 171: 571-8
|
|
|
|
|